Abstract
[Display omitted]
•Two groups of thiazolidin-4-ones 4a–c and 8a–e were designed and synthesized.•Compounds 8c and 8d showed the best overall in vitro COX-2 selectivity and in vivo activities.•8c and 8d showed reduction in ulcerogenic potential versus celecoxib=85%, 92% respectively.•8c and 8d could be used as a lead compound for developing new anti-inflammatory agents.
Two series of new thiazolidin-4-one derivatives 4a–c and 8a–e were designed and prepared. All the synthesized compounds were evaluated for their in vitro COX-2 selectivity and anti-inflammatory activity in vivo. Compounds 8c and 8d showed the best overall in vitro COX-2 selectivity (selectivity indexes of 4.56 and 5.68 respectively) and in vivo activities (edema inhibition %=61.8 and 67 after 3h, respectively) in comparison with the reference drug celecoxib (S.I.=7.29, edema inhibition %=60 after 3h). In addition, 8c and 8d were evaluated for their mean effective anti-inflammatory doses (ED50=27.7 and 18.1μmol/kg respectively, celecoxib ED50=28.2μmol/kg) and ulcerogenic liability (reduction in ulcerogenic potential versus celecoxib=85%, 92% respectively. Molecular docking studies were performed and the results were in agreement with that obtained from the in vitro COX inhibition assays.